Table 2.
Patient characteristics and EGFR mutation status.
| Number | EGFR mutation (n, %) | P-value | |
|---|---|---|---|
| Gender | |||
| Male | 112 | 17, 15.2% | P < 0.0001 |
| Female | 86 | 35, 40.7% | |
| Age | |||
| <65 | 80 | 23, 28.8% | P = 0.5156 |
| 65≤ | 118 | 29, 24.6% | |
| Histology | |||
| Adenocarcinoma | 169 | 50, 29.6% | P = 0.0107 |
| Nonadenocarcinoma | 29 | 2, 6.9% | |
| Smoking status | |||
| Never | 74 | 29, 39.2% | P = 0.0139 |
| Ex/Current | 124 | 23, 18.5% | |
| Clinical stage of NSCLC | |||
| I-IIIA | 63 | 21, 33.3% | P = 0.1649 |
| IIIB-IV | 135 | 31, 22.9% | |
| Chest CT | |||
| Normal | 122 | 43, 35.2% | P = 0.0011 |
| Emphysema | 59 | 8, 13.6% | |
| Fibrosis | 17 | 1, 5.8% |